ALLURION TECHNOLOGIES, INC.

Overview

Compare with BIOTRICITY INC., Profound Medical Corp. or Vivos Therapeutics, Inc., or pick any stock.

• TickerALUR on OTC¹
• IndustrySurgical & Medical Instruments & Apparatus¹
• HeadquartersNatick, Massachusetts¹
• Incorporated inDE²
• Business address11 Huron Dr Ste 200, Natick, Ma 01760²
• Filer category, Emerging growth company²
• Legal formCorporation

See how the biggest companies compare on our leaderboards

Corporate structure

ALLURION TECHNOLOGIES, INC. sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What ALLURION TECHNOLOGIES, INC. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

Real estate and locations

Investments

Inventory

Properties, in its own words

Our corporate headquarters are located in Natick, Massachusetts, where we lease approximately 9,900 square feet of office space pursuant to a lease agreement that commenced on June 15, 2016 and expires on February 28, 2028. We also lease approximately 10,200 square feet of manufacturing space in Natick, Massachusetts pursuant to a lease agreement that commenced on January 8, 2018 and expires on February 28, 2028. We also lease approximately 9,800 square feet of warehouse space in Hudson, Massachusetts pursuant to a lease agreement that commenced on February 11, 2022 and expired on February 28, 2026. We believe that our existing facilities are suitable and adequate for our needs.

Item 2 of the 10-K filed Mar 30, 2026.⁹

Leadership

Who has led ALLURION TECHNOLOGIES, INC., and when. Pick a name to see everywhere that person has worked.

• Chief executive officerShantanu Gaur Aug 1, 2023 to now¹⁰
• Chief financial officerChristopher J. Geberth Aug 1, 2023 to Aug 1, 2023¹¹
• Chief operating officerOjas Buch Jun 5, 2024 to now¹²

Named in SEC Form D filings

People the company listed in its private-offering notices.

• DirectorR. Jason Douglas Richey named Feb 7, 2025 to Nov 26, 2025²⁵
• DirectorDouglas Hudson Larson named Dec 22, 2023²⁶

Former names

• ALLURION TECHNOLOGIES HOLDINGS, INC.Feb 9, 2023 to Aug 1, 2023²

Timeline

1. Aug 24, 20268-K Executive or director change²⁷
2. Jul 24, 20268-K Entered a material agreement; Ended a material agreement; Unregistered sale of shares²⁸
3. Jul 23, 20268-K Executive or director change²⁹
4. Jul 7, 20268-K Executive or director change³⁰
5. Jun 30, 20268-K Executive or director change³¹
6. Jun 17, 20268-K Change to shareholders' rights; Bylaws or fiscal year changed; Other events³²
7. May 27, 20268-K Change of auditor³³
8. Mar 12, 20268-K Listing notice or transfer; Other events³⁴
9. Mar 2, 20268-K Listing notice or transfer; Other events³⁵
10. Feb 25, 20268-K Entered a material agreement; Unregistered sale of shares; Change to shareholders' rights³⁶
11. Feb 23, 20268-K Regulation FD disclosure³⁷
12. Jan 12, 20268-K Results of operations³⁸
13. Aug 1, 2023New chief executive Shantanu Gaur becomes CEO¹⁰

Calendar

When it reported results

1. Jan 12, 2026Reported quarterly or annual results³⁸
2. Nov 12, 2025Reported quarterly or annual results³⁹
3. Aug 13, 2025Reported quarterly or annual results⁴⁰
4. Aug 7, 2025Reported quarterly or annual results⁴¹
5. May 14, 2025Reported quarterly or annual results⁴²
6. Mar 26, 2025Reported quarterly or annual results⁴³
7. Jan 17, 2025Reported quarterly or annual results⁴⁴
8. Jan 8, 2025Reported quarterly or annual results⁴⁵

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

318 filings to the SEC since October 2021: 6 annual reports, 13 quarterly reports, 56 major events, 40 insider forms, 22 large holders, 3 private raises, 178 other. The latest 20:

1. Oct 13, 202625-NSE EDGAR
2. Sep 2, 2026SCHEDULE 13D/A EDGAR
3. Aug 24, 20268-K EDGAR
4. Aug 14, 2026NT 10-Q EDGAR
5. Jul 24, 20268-K EDGAR
6. Jul 23, 2026SCHEDULE 13D/A EDGAR
7. Jul 23, 20264 EDGAR
8. Jul 23, 20268-K EDGAR
9. Jul 7, 20268-K EDGAR
10. Jun 30, 20268-K EDGAR
11. Jun 17, 20268-K EDGAR
12. May 27, 20268-K EDGAR
13. May 15, 202610-Q EDGAR
14. Mar 30, 202610-K EDGAR
15. Mar 12, 20268-K EDGAR
16. Mar 2, 2026SCHEDULE 13D/A EDGAR
17. Mar 2, 20268-K EDGAR
18. Feb 25, 20268-K EDGAR
19. Feb 23, 20268-K EDGAR
20. Feb 17, 20265 EDGAR

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

4 open-market trades by officers, directors and large owners since October 2021: 2 buys and 2 sales. Grants, option exercises and gifts are left out.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

• RTW INVESTMENTS, LPSCHEDULE 13D/A, 14 filings Aug 11, 2023 to Sep 2, 2026⁴⁶
• ARMISTICE CAPITAL, LLCSCHEDULE 13G/A, 4 filings Aug 9, 2024 to May 15, 2025⁴⁷
• Leavitt Equity Partners III, L.P.SCHEDULE 13G, 1 filing Feb 26, 2025⁴⁸
• CITADEL ADVISORS LLCSC 13G/A, 3 filings Dec 26, 2023 to Nov 14, 2024⁴⁹

Executive pay

What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.

Funding

Where the company's money came from, by calendar year: private offerings filed with the SEC, federal grants, loans, contracts and other assistance from USAspending.gov, and PPP loans from the SBA. Each bar links to the records below.

Private raises

Private offerings the company reported to the SEC on Form D. The amount is what the latest filing says was sold so far, charted in the year of the first sale. Covers filings since Oct 1, 2021.

1. Nov 14, 2025Raised $5 million in a private offering of equity²⁵ Form D: 16 investors so far Form D
2. Jan 27, 2025Raised $7.4 million in a private offering of securities⁵¹ Form D: 14 investors so far Form D
3. Dec 18, 2023Raised $122,513 in a private offering of equity²⁶ Form D: $100.1 million offered in all Form D

PPP loans

Paycheck Protection Program loans of $150,000 and up, approved April 2020 to July 2021, from the SBA⁵². Matched to this company by name and state.

1. Apr 14, 2020$1.0M PPP loan (first draw) from Needham Bank⁵²To ALLURION TECHNOLOGIES, INC., Natick MA; $1.0M forgiven Feb 17, 2021
2. Feb 8, 2021$1.0M PPP loan (second draw) from Needham Bank⁵²To ALLURION TECHNOLOGIES INC., Natick MA; $1.0M forgiven Jul 21, 2021

SEC filer profile

How ALLURION TECHNOLOGIES, INC. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

• Name on EDGARALLURION TECHNOLOGIES, INC.¹
• CIK0001964979
• Employer ID (EIN)92-2182207⁹
• Filer statusNon-accelerated filer an emerging growth company; a smaller reporting company; not a shell company⁹
• Incorporated inDelaware⁹
• Fiscal year endsDecember 31¹
• Industry code (SIC)3841 Surgical & Medical Instruments & Apparatus¹
• SEC reviewing officeOffice of Industrial Applications and Services, Division of Corporation Finance¹
• Business address11 Huron Dr Ste 200, Natick, MA 01760¹
• Phone508-647-4000¹
• Shares outstanding15,006,253 as of May 12, 2026⁷
• Public float$20.7M as of Jun 30, 2025⁹
• AuditorDeloitte & Touche LLP, Boston, Massachusetts PCAOB ID 34; no auditor attestation of internal control over financial reporting⁹
• On EDGAR sinceFeb 9, 2023¹
• Filings318 in all: 424B3 (77), 8-K (55), 4 (21), 3 (15), CORRESP (15), EFFECT (12), UPLOAD (12), SCHEDULE 13D/A (10)¹
  All 46 form types

  10-Q (9), 425 (7), S-1/A (7), S-4/A (6), S-1 (5), 10-Q/A (4), POS AM (4), 10-K (3), 10-K/A (3), 424B5 (3), D (3), DEF 14A (3), NT 10-Q (3), PRE 14A (3), S-3 (3), SC 13D/A (3), SC 13G/A (3), 4/A (2), 5 (2), ARS (2), DEFA14A (2), DRS (2), S-8 (2), SC 13G (2), SCHEDULE 13G/A (2), 144 (1), 25-NSE (1), 424B4 (1), 8-A12B (1), 8-K/A (1), CERT (1), DRSLTR (1), PRER14A (1), RW (1), S-3/A (1), S-4 (1), SC 13D (1), SCHEDULE 13G (1)

• Latest filingsAnnual report (10-K) Mar 30, 2026
  Quarterly report (10-Q) May 15, 2026
  Proxy statement (DEF 14A) Nov 24, 2025
  Latest 8-K (8-K) Aug 24, 2026

Securities registered for trading

From the cover page of the 10-K filed Mar 30, 2026 (Section 12(b) of the Exchange Act).⁹

Risk factors and legal proceedings

The risks ALLURION TECHNOLOGIES, INC. names in Item 1A of its 10-K filed Mar 30, 2026: 74 risks under these headings, as written.⁹

• Risks Related to the Development and Commercialization of Our Products
• We have a limited operating history and may face difficulties encountered by companies early in their commercialization in competitive and rapidly evolving markets.
• We have incurred losses to date and expect to incur losses for the foreseeable future, our ability to achieve and maintain profitability depends on the commercial success of the Allurion Smart Capsule, and we expect our revenues to continue to be driven primarily by sales of the Allurion Smart Capsule.
• The failure of the Allurion Smart Capsule to achieve and maintain market acceptance, especially in the United States where we just received FDA approval in February 2026, could result in us achieving sales below our expectations, which would cause our business, financial condition and operating results to be materially and adversely affected.
• Commercial success of the Allurion Smart Capsule in the United States or elsewhere depends on our ability to accurately forecast customer demand and manufacture sufficient quantities of product that patients and health care providers request, and to manage inventory effectively. The failure to do so could have a material adverse effect on our business, financial condition, results of operations and growth prospects.
• Except for limited exceptions, we do not expect health care providers or patients will receive third-party reimbursement for treatment with our products in the near future. As a result, we expect that our success will depend on the ability and willingness of health care providers to adopt self-pay practice management infrastructure and of patients to pay out-of-pocket for treatment with our products.
• Changes in coverage and reimbursement for obesity treatments and procedures could affect the adoption of the Allurion Program and our future revenues.
• A substantial proportion of our sales are through third-party distributors, and we do not have direct control over the efforts these distributors may use to sell our products. If our relationships with these distributors deteriorate, or if these distributors fail to sell our products or engage in activities that harm our reputation, or fail to adhere to medical device regulations, our financial results may be negatively affected.
• In certain large markets, we engage in direct sales efforts. We may fail to maintain and develop our direct sales force, and our revenues and financial outcomes could suffer as a result. Furthermore, our direct sales personnel may not effectively sell our products.
• The effectiveness and safety of the Allurion Smart Capsule depends critically on our ability to educate health care providers on its safe and proper use. If we are unable to do so, we may not achieve our expected growth and may be subject to risks and liabilities.
• The misuse or off-label use of our products may harm our image in the marketplace, result in injuries that lead to product liability suits or result in costly investigations and sanctions by regulatory bodies if we are deemed to have engaged in the promotion of these uses, any of which could be costly to our business.
• The Allurion Gastric Balloon System, featuring the Allurion Smart Capsule, is approved in more than 80 countries, including the United States and the European Union. Maintaining regulatory approval in these jurisdictions may require further clinical trials and investment and cannot be guaranteed.

Legal proceedings

From time to time, we may become involved in legal proceedings or be subject to claims arising in the ordinary course of our business. We are not currently a party to any material legal proceedings. Regardless of outcome, such proceedings or claims can have an adverse impact on us because of defense and settlement costs, diversion of resources and other factors, and there can be no assurances that favorable outcomes will be obtained.

On August 12, 2025, Vanderbilt University Medical Center (“Vanderbilt”) filed a complaint against us in the United States District Court for the Middle District of Tennessee, captioned Vanderbilt University Medical Center v. Allurion Technologies, Inc., d/b/a Allurion. Vanderbilt’s complaint alleges that we breached the Clinical Trial Agreement, dated June 30, 2022, by and between us and Vanderbilt, related to the clinical trial for the Allurion Balloon by failing to reimburse medical expenses incurred in treating a patient enrolled in such trial at Vanderbilt. Vanderbilt is seeking damages of approximately $2.5 million. We intend to defend against such claims vigorously, but we cannot be sure that we will be successful in prevailing in such proceeding or that it will not incur material costs in defending against such allegations.

The opening of Item 3, Legal Proceedings.⁹